In TNBC cohorts, ABCB1 upregulation correlates with poorer response to neoadjuvant therapy (pCR rates < 20% vs. >50% in low-expressors) and reduced overall survival (HR 1.8; 95% CI 1.2–2.7), as ABCB1 expression is induced by stress signals like NF-κB activation in the tumor microenvironment (TME) [54,55]. Here, ABCB1 is linked to neoplasm.